Sancilio & Company, Inc. (SCI) is an integrated specialty pharmaceutical company. We are uniquely focused on diseases that impact fatty acid balance within the body and we have developed Advanced Lipid Technologies® (ALT®) to increase bioavailability of lipids and lipophilic materials while minimizing the effects of food on absorption and the liver.
Our most advanced applications of ALT® include:
* Orphan Drug Status granted by the U.S. FDA in 2015
Executive Vice President & Chief Financial Officer